RMD RESMED INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 943819 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.0%
TTM net income YoY10.8%
TTM EPS YoY12.4%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR20.7%
Margins
Gross margin61.1%
Operating margin33.0%
Net margin27.8%
FCF margin28.1%
EBITDA margin36.4%
Returns
ROE26.4%
ROA19.3%
ROIC (approx.)27.9%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets27.6%
Debt / equity0.07x
Current ratio2.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio-2.2%
Payout ratio22.4%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B |
| Cost of revenue | $2.20B | $2.09B | $2.03B | $1.87B | $1.55B |
| Gross profit | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B |
| R&D expense | $378.29M | $331.28M | $307.52M | $287.64M | $253.57M |
| SG&A expense | $1.12B | $993.05M | $917.14M | $874.00M | $737.51M |
| Operating income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B |
| Pretax income | $1.92B | $1.68B | $1.26B | $1.10B | $960.48M |
| Income tax | $396.12M | $276.84M | $243.85M | $204.11M | $181.05M |
| Net income | $1.52B | $1.40B | $1.02B | $897.56M | $779.44M |
| EBITDA | $2.09B | $1.88B | $1.50B | $1.30B | $1.16B |
| EPS (basic) | 10.47 | 9.55 | 6.94 | 6.12 | 5.34 |
| EPS (diluted) | 10.43 | 9.51 | 6.92 | 6.09 | 5.30 |
| Dividends declared per share | 2.40 | 2.12 | 1.92 | 1.76 | 1.68 |
| Weighted avg. shares (diluted) | 146.05M | 147.34M | 147.55M | 147.46M | 147.04M |
| Banking | |||||
| Net interest income | — | — | — | -$47.38M | -$22.31M |
| Balance sheet | |||||
| Cash & equivalents | $1.47B | $1.21B | $238.36M | $227.89M | $273.71M |
| Receivables | $1.04B | $939.49M | $837.27M | $704.91M | $575.95M |
| Inventory | $945.80M | $927.71M | $822.25M | $998.01M | $743.91M |
| Current assets | $4.32B | $3.51B | $2.36B | $2.37B | $1.93B |
| PP&E, net | $581.83M | $550.79M | $548.02M | $537.86M | $498.18M |
| Goodwill | $2.91B | $3.05B | $2.84B | $2.77B | $1.94B |
| Intangibles | $452.74M | $464.86M | $485.90M | $552.34M | $345.94M |
| Total assets | $8.97B | $8.17B | $6.87B | $6.75B | $5.10B |
| Current liabilities | $1.40B | $1.02B | $910.65M | $758.53M | $689.30M |
| Short-term debt | $259.95M | $9.90M | $9.90M | $9.90M | $9.92M |
| Long-term debt | $399.42M | $658.39M | $697.31M | $1.43B | $765.33M |
| Total debt | $659.37M | $668.29M | $707.21M | $1.44B | $775.24M |
| Total liabilities | $2.38B | $2.21B | $2.01B | $2.62B | $1.74B |
| Shareholders' equity | $6.59B | $5.97B | $4.86B | $4.13B | $3.36B |
| Net debt | -$809.87M | -$541.16M | $468.85M | $1.21B | $501.53M |
| Shares outstanding | 144.24M | 146.39M | 146.90M | 147.06M | 146.41M |
| Cash flow statement | |||||
| Operating cash flow | $1.81B | $1.75B | $1.40B | $693.30M | $351.15M |
| Capital expenditure | $156.28M | $89.86M | $99.46M | $119.67M | $134.84M |
| Free cash flow | $1.65B | $1.66B | $1.30B | $573.63M | $216.31M |
| Investing cash flow | -$545.20M | -$200.04M | -$269.78M | -$1.16B | -$229.92M |
| Financing cash flow | -$1.01B | -$606.25M | -$1.12B | $422.87M | -$128.36M |
| Depreciation & amortization | $201.34M | $198.47M | $176.87M | $165.16M | $159.61M |
| Stock-based compensation | $104.35M | $91.66M | $80.18M | $71.14M | $65.26M |
| Dividends paid | $349.66M | $310.88M | $282.32M | $258.28M | $245.34M |
| Share buybacks | $700.04M | $300.02M | $150.01M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.